Sitemap
Pages
News
- Evgen Pharma “cash runway in pretty good shape”
- Evgen Pharma Encouraging interim data from the STEM trial
- Evgen Pharma have ‘many shots at goal’, solving unmet needs in the pharmaceutical industry
- Evgen Pharma Licensing and Clinical Programme Update
- Evgen Pharma makes progress on two fronts in the field of cancer
- Evgen Pharma now has the financial runway to exploit its technology after ‘transformative’ City fundraiser
- Evgen Pharma Post AGM Presentation
- Evgen Pharma presents 2022 clinical trials plans and progress with US and UK regulators
- Evgen Pharma presents at the Proactive One2One Investor Forum
- Evgen Pharma talks through clinical milestones and financial results from its 2022 full-year report
- Evgen Pharma updates on the ‘STAR’ trial for Covid-19, Glioma research and key breast cancer drug
- Evgen Pharma: Johns Hopkins research further assesses the potential of company’s drug to treat COVID-19
- Evgen portfolio update on core field of cancer, ‘the R&D is entirely on plan and on budget’
- Going for Growth: Evgen Pharma CEO, Huw Jones, interviewed by ShareBuyers
- Interim Results 2022-23
- Investor Meet Company Presentation